Probi AB (publ) (PROB.ST)
SEK 347.0
(-0.29%)
SEK 347.0
(-0.29%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 53.79 Million SEK | -23.44% |
| 2022 | 70.26 Million SEK | -9.44% |
| 2021 | 77.58 Million SEK | 74.56% |
| 2020 | 44.44 Million SEK | -27.33% |
| 2019 | 61.16 Million SEK | -48.36% |
| 2018 | 118.46 Million SEK | -32.64% |
| 2017 | 175.86 Million SEK | -22.08% |
| 2016 | 225.71 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| 2007 | - SEK | -100.0% |
| 2006 | 3.6 Million SEK | 2272.37% |
| 2005 | 152 Thousand SEK | 10.95% |
| 2004 | 137 Thousand SEK | 0.0% |
| 2003 | 137 Thousand SEK | 197.83% |
| 2002 | 46 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 20.28 Million SEK | -8.56% |
| 2024 Q2 | 88.84 Million SEK | 70.22% |
| 2024 Q1 | 52.19 Million SEK | -2.98% |
| 2023 Q3 | 61.12 Million SEK | -6.0% |
| 2023 FY | 53.79 Million SEK | -23.44% |
| 2023 Q2 | 65.02 Million SEK | -1.75% |
| 2023 Q1 | 66.18 Million SEK | -5.82% |
| 2023 Q4 | 53.79 Million SEK | -11.99% |
| 2022 Q3 | 77.45 Million SEK | -0.21% |
| 2022 Q2 | 77.62 Million SEK | 2.54% |
| 2022 FY | 70.26 Million SEK | -9.44% |
| 2022 Q4 | 70.26 Million SEK | -9.28% |
| 2022 Q1 | 75.7 Million SEK | -2.43% |
| 2021 Q3 | 60.1 Million SEK | -3.09% |
| 2021 Q2 | 62.02 Million SEK | 30.94% |
| 2021 Q1 | 47.36 Million SEK | 6.57% |
| 2021 Q4 | 77.58 Million SEK | 29.08% |
| 2021 FY | 77.58 Million SEK | 74.56% |
| 2020 Q3 | 50.64 Million SEK | -8.95% |
| 2020 Q1 | 62.64 Million SEK | 2.41% |
| 2020 FY | 44.44 Million SEK | -27.33% |
| 2020 Q2 | 55.62 Million SEK | -11.2% |
| 2020 Q4 | 44.44 Million SEK | -12.24% |
| 2019 Q4 | 61.16 Million SEK | 0.0% |
| 2019 FY | 61.16 Million SEK | -48.36% |
| 2019 Q3 | - SEK | -100.0% |
| 2019 Q2 | 19.75 Million SEK | -66.29% |
| 2019 Q1 | 58.61 Million SEK | -50.52% |
| 2018 FY | 118.46 Million SEK | -32.64% |
| 2018 Q4 | 118.46 Million SEK | -9.8% |
| 2018 Q3 | 131.32 Million SEK | -31.55% |
| 2018 Q2 | 191.84 Million SEK | 7.29% |
| 2018 Q1 | 178.8 Million SEK | 1.67% |
| 2017 Q4 | 175.86 Million SEK | 1.61% |
| 2017 Q1 | 221.81 Million SEK | -1.73% |
| 2017 Q3 | 173.07 Million SEK | -4.21% |
| 2017 Q2 | 180.69 Million SEK | -18.54% |
| 2017 FY | 175.86 Million SEK | -22.08% |
| 2016 FY | 225.71 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q4 | 225.71 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2007 FY | - SEK | -100.0% |
| 2006 FY | 3.6 Million SEK | 2272.37% |
| 2005 FY | 152 Thousand SEK | 10.95% |
| 2004 FY | 137 Thousand SEK | 0.0% |
| 2003 FY | 137 Thousand SEK | 197.83% |
| 2002 FY | 46 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | -511.33% |
| Enzymatica AB (publ) | 26.1 Million SEK | -106.095% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -12238.761% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | -184.159% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -1035.677% |
| Nanexa AB (publ) | 4.03 Million SEK | -1234.251% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 88.646% |
| Swedencare AB (publ) | 1.65 Billion SEK | 96.756% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.737% |
| Toleranzia AB | 850 Thousand SEK | -6229.059% |
| Vivesto AB | 8.16 Million SEK | -558.631% |